Anti-TARC / CCL17 Antibody [I02-2A4] (A280672)

Anti-TARC / CCL17 Antibody [I02-2A4]

Mouse monoclonal [I02-2A4] antibody to TARC / CCL17.

This antibody recognises C-C motif chemokine 17, also known as TARC and SCYA17. CCL17 is a C-C chemokine highly expressed by the thymus and other cell types, including fibroblasts. CCL17 induces and enhances a broad spectrum of immune reactions, including some contact hypersensitivity reactions, allograft rejections, inflammatory bowel disease, atopic dermatitis and atherosclerosis. Therapeutic use of antibodies to neutralize CCL17 can block influx of T cells and ameliorate the impact of various diseases. Upregulation of CCL17 has been reported in breast cancer, and predicts a decrease in overall survival for patients with breast cancer. The purified Mouse anti Human CCL17 antibody, clone I02-2A4 (MCA6180GA) can be used as a capture antibody in a sandwich ELISA with the biotinylated Mouse anti Human CCL17 antibody, clone I11-2A1 (MCA6181B) as the detection antibody.

Immunoassay

Immunoassay: 1 µg/ml

Human

E. coli derived recombinant human full length CCL17 (Ala24-Ser94).

Mouse

Monoclonal

I02-2A4

IgG1

Protein G affinity chromatography of tissue culture supernatant.

1 mg/ml

Liquid

Supplied in Phosphate Buffered Saline with 0.09% Sodium Azide.

Shipped at ambient temperature. Upon delivery aliquot and store at -20°C. When thawed, aliquot the sample as needed. Short term (up to 4 weeks): store at 4°C. Long term: store at -20°C. Avoid freeze / thaw cycles. Storage in frost free freezers is not recommended.

Mouse anti Human CCL17 antibody, clone I02-2A4recognizes C-C motif chemokine 17, also known as TARC and SCYA17. CCL17 is a C-C chemokine highly expressed by the thymus and other cell types, including fibroblasts (Li et al. 2019). CCL17 induces and enhances a broad spectrum of immune reactions, including some contact hypersensitivity reactions, allograft rejections, inflammatory bowel disease, atopic dermatitis and atherosclerosis (Scheu et al. 2017). Therapeutic use of antibodies to neutralize CCL17 can block influx of T cells and ameliorate the impact of various diseases (Teplyakov et al. 2017). Upregulation of CCL17 has been reported in breast cancer, and predicts a decrease in overall survival for patients with breast cancer (Li et al. 2019).The purified Mouse anti Human CCL17 antibody, clone I02-2A4 (MCA6180GA) can be used as a capture antibody in a sandwich ELISA with the biotinylated Mouse anti Human CCL17 antibody, clone I11-2A1 (MCA6181B) as the detection antibody.